In this episode, Subhi breaks down ICH Q12, the guideline focused on post-approval change management and pharmaceutical product lifecycle management.

The core question behind ICH Q12 is simple: once a product is approved, what is actually binding, what is supporting information, and how should future changes be managed?

This episode covers the major Q12 concepts, including reporting categories, Established Conditions, supporting information, Post-Approval Change Management Protocols, the Product Lifecycle Management document, and the role of the Pharmaceutical Quality System.

Subhi also discusses why Q12 matters for drug-device combination products, where lifecycle changes may involve CMC information, device constituent parts, functional performance characteristics, and the broader control strategy.

Key topics covered:

Why post-approval change can become difficult after approval
How ICH Q12 supports more predictable lifecycle management
Reporting categories for post-approval CMC changes
Established Conditions versus supporting information
Examples of EC candidates, including CQAs, CPPs, material attributes, methods, sites, and process information
Why overcommitting or undercommitting ECs creates lifecycle risk
How PACMPs help companies plan future changes
What belongs in the PLCM document
How ICH Q12 applies to drug-device combination products
Why a strong PQS is essential for making Q12 work

Timestamps:

00:00 Introduction to ICH Q12

00:46 Why post-approval change gets difficult

02:45 Reporting categories

03:14 Established Conditions vs supporting information

04:10 EC examples: CQAs, CPPs, methods, sites, and process information

05:32 Post-Approval Change Management Protocols

06:38 PLCM document

08:08 Drug-device combination product callout

10:11 PQS and change management

10:28 Closing thoughts

Questions or feedback? Email subhi@letscombinate.com

Source referenced in this episode: ICH Q12, Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management, Final version adopted 20 November 2019. Screenshots shown in this video are from the ICH Q12 guideline and are included for educational commentary. https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf

Subhi Saadeh is the Founder and Principal at Let’s Combinate, where he helps teams develop and control drug-device combination products by aligning quality systems, development, and regulatory expectations across drug and device domains. He is a consultant, auditor, trainer, and speaker with experience across Pfizer, Gilead, and Baxter, supporting the development and launch of combination products across vaccines, biologics, and generics.